Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Sell
35
ILMN Quote, Financials, Valuation and Earnings
Last price:
$136.64
Seasonality move
:
-1.2%
Day range:
$131.75 - $138.00
52-week range:
$100.09 - $156.66
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.98x
P/B ratio:
10.25x
Volume:
1.3M
Avg. volume:
2M
1-year change:
1.65%
Market cap:
$21.8B
Revenue:
$4.5B
EPS (TTM):
-$9.96
Analysts' Opinion
-
Consensus RatingIllumina has received a consensus rating of Hold. The company's average rating is a Hold based on 9 Buy ratings, 12 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $162.80, Illumina has an estimated upside of 18.52% from its current price of $137.37.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $120.00 representing 100% downside risk from its current price of $137.37.
Fair Value
-
According to the consensus of 21 analysts, Illumina has 18.52% upside to fair value with a price target of $162.80 per share.
ILMN vs. S&P 500
-
Over the past 5 trading days, Illumina has underperformed the S&P 500 by -3.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Illumina does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Illumina revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Illumina reported revenues of $1.1B.
Earnings Growth
-
Illumina earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Illumina reported earnings per share of $4.42.
Enterprise value:
22.8B
EV / Invested capital:
--
Price / LTM sales:
4.98x
EV / EBIT:
--
EV / Revenue:
5.20x
PEG ratio (5yr expected):
-0.35x
EV / Free cash flow:
41.82x
Price / Operating cash flow:
40.00x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.8B
Return On Assets:
-18.69%
Net Income Margin (TTM):
-36.08%
Return On Equity:
-37.83%
Return On Invested Capital:
-26.73%
Operating Margin:
23.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $4.7B | $4.5B | $4.4B | $1.1B | $1.1B | |
| Gross Profit | $3.1B | $2.7B | $2.8B | $684M | $745M | |
| Operating Income | $501M | -$192M | $239M | $66M | $253M | |
| EBITDA | -$3.7B | -$621M | -$1B | -$655M | $826M | |
| Diluted EPS | -$26.40 | -$7.12 | -$9.96 | -$4.77 | $4.42 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.3B | $2.5B | $2.5B | $2.5B | $2.4B | |
| Total Assets | $7.4B | $15.1B | $11.3B | $10.1B | $6B | |
| Current Liabilities | $1.1B | $914M | $2.7B | $1.5B | $975M | |
| Total Liabilities | $2.7B | $4.5B | $4.5B | $4.2B | $3.9B | |
| Total Equity | $4.7B | $10.6B | $6.7B | $5.9B | $2.1B | |
| Total Debt | $1.2B | $1.7B | $1.7B | $1.5B | $2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $527M | $401M | $697M | $139M | $316M | |
| Cash From Investing | -$489M | -$248M | -$215M | -$53M | -$41M | |
| Cash From Financing | -$85M | -$227M | -$550M | -$707M | -$332M | |
| Free Cash Flow | $79M | $169M | $546M | $95M | $284M | |
ILMN
Sector
Market Cap
$21.8B
$45.4M
Price % of 52-Week High
87.69%
46.67%
Dividend Yield
0%
0%
Shareholder Yield
0.45%
-0.74%
1-Year Price Total Return
1.65%
-33.9%
Beta (5-Year)
1.109
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$138.55
200-day SMA
Buy
Level
$127.47
Bollinger Bands (100)
Sell
Level
130.76 - 146.02
Chaikin Money Flow
Buy
Level
389.7M
20-day SMA
Buy
Level
$136.51
Relative Strength Index (RSI14)
Sell
Level
48.39
ADX Line
Buy
Level
18.8
Williams %R
Neutral
Level
-68.6352
50-day SMA
Sell
Level
$141.14
MACD (12, 26)
Sell
Level
-0.75
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
297.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.1838)
Sell
CA Score
(Annual)
Level (-0.488)
Buy
Beneish M-Score
(Annual)
Level (-3.1214)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.2073)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina’s high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Stock Forecast FAQ
In the current month, ILMN has received 9 Buy ratings 12 Hold ratings, and 0 Sell ratings. The ILMN average analyst price target in the past 3 months is $162.80.
-
Where Will Illumina Stock Be In 1 Year?
According to analysts, the consensus estimate is that Illumina share price will rise to $162.80 per share over the next 12 months.
-
What Do Analysts Say About Illumina?
Analysts are divided on their view about Illumina share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Illumina is a Sell and believe this share price will drop from its current level to $120.00.
-
What Is Illumina's Price Target?
The price target for Illumina over the next 1-year time period is forecast to be $162.80 according to 21 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 12 analysts rate the stock a Hold.
-
Is ILMN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Illumina is a Hold. 12 of 21 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ILMN?
You can purchase shares of Illumina via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Illumina shares.
-
What Is The Illumina Share Price Today?
Illumina was last trading at $136.64 per share. This represents the most recent stock quote for Illumina. Yesterday, Illumina closed at $137.37 per share.
-
How To Buy Illumina Stock Online?
In order to purchase Illumina stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will T-Mobile Stock Recover?
Last year was a stellar year for telecom giant T-Mobile…
Why Is Stanley Druckenmiller Buying Citigroup?
As recently as 2020, few analysts could have predicted that…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
NUTX alert for Jan 17
Nutex Health [NUTX] is up 2.83% over the past day.
Buy
53
QMCO alert for Jan 17
Quantum [QMCO] is down 15.61% over the past day.
Sell
34
NGVT alert for Jan 17
Ingevity [NGVT] is up 1.31% over the past day.
